BRD4 and acute lymphoblastic leukemia: This study suggests that BRD4 and HCP5 are potential therapeutic targets for T-ALL, and GNE-987 provides a novel therapeutic strategy by targeting this regulatory axis, laying the foundation for precision therapy in T-ALL.